GlassScriptPhysician profile
Amy F Taub
NPI 1215967765
$81,492.26
in general payments reported to CMS, 2019-2025
33 companies · $10K in 2025
The $10K reported for 2025 was more than what 92% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,418 · 2020: $7,588 · 2021: $12K · 2022: $21K · 2023: $15K · 2024: $8,992 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,232 · Food and Beverage: $5,976 · Travel and Lodging: $1,968 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,453.33 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,231.80 |
| Food and Beverage | $5,975.83 |
| Travel and Lodging | $1,967.58 |
| Education | $109.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $33,824.05 | 2019-2022 | |
| Abbvie INC. | $31,837.10 | 2019-2025 | Botox, Rinvoq, Skyrizi |
| Solta Medical, A Division of Bausch Health US, LLC | $5,804.60 | 2019-2025 | |
| Merz North America, INC. | $2,637.70 | 2019-2023 | Xeomin |
| Galderma Laboratories, L.P. | $2,599.27 | 2019-2025 | Nemluvio, Aklief |
| Sun Pharmaceutical Industries INC. | $592.19 | 2019-2025 | Ilumya, Winlevi |
| Lilly USA, LLC | $528.84 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $493.68 | 2023-2025 | |
| Janssen Biotech, INC. | $378.11 | 2019-2025 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $343.95 | 2019-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $249.37 | 2022-2025 | Sotyktu |
| Pfizer INC. | $248.37 | 2021-2025 | |
| Revance Therapeutics, INC. | $215.51 | 2024-2025 | Daxxify |
| Ucb, INC. | $206.77 | 2019-2024 | Bimzelx |
| Amgen INC. | $183.52 | 2019-2025 | Otezla, Otezla |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $174.91 | 2020-2025 | Adbry |
| Novartis Pharmaceuticals Corporation | $169.50 | 2019-2022 | |
| Biofrontera INC. | $153.71 | 2019-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Strata Skin Sciences, INC. | $142.67 | 2020-2024 | Xtrac |
| Arcutis Biotherapeutics, INC. | $121.36 | 2023-2025 | Zoryve |
| Almirall LLC | $104.05 | 2019-2023 | Seysara |
| Endo Pharmaceuticals INC. | $97.07 | 2019 | |
| Epi Health, LLC | $63.72 | 2019-2022 | |
| Dermavant Sciences, INC. | $60.23 | 2024 | Vtama |
| Incyte Corporation | $56.94 | 2021-2025 | Opzelura |
| Celgene Corporation | $53.71 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $33.18 | 2019-2020 | |
| Organon LLC | $27.41 | 2025 | |
| Fidia Pharma USA INC. | $25.57 | 2023 | Hymovis, Triluron |
| Mylan Pharmaceuticals INC. | $19.32 | 2019 | |
| Dusa Pharmaceuticals, INC. | $17.11 | 2019 | |
| Genentech USA, INC. | $15.00 | 2019 | |
| Janssen Scientific Affairs, LLC | $13.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Taub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.